EP0007450A1
(de)
*
|
1978-07-07 |
1980-02-06 |
Ciba-Geigy Ag |
Azatetracyclische Carbonitrile, ihre Herstellung, pharmazeutische Präparate, die diese enthalten und deren Verwendung
|
DE3069086D1
(de)
*
|
1979-12-10 |
1984-10-04 |
Ciba Geigy Ag |
Azatetracyclic carbonitriles
|
FR2504140A1
(fr)
*
|
1981-04-16 |
1982-10-22 |
Centre Nat Rech Scient |
Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
|
EP0094668B1
(de)
*
|
1982-05-18 |
1987-07-08 |
F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft |
Pyrrolo(3,4-d)(2)benzazepin-Derivate
|
JPS62101941U
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
*
|
1985-12-16 |
1987-06-29 |
|
|
IE62754B1
(en)
*
|
1988-08-26 |
1995-02-22 |
Akzo Nv |
Tetracyclic antidepressants
|
EP0569096A1
(en)
*
|
1992-05-08 |
1993-11-10 |
Akzo Nobel N.V. |
Depot preparation
|
CN1046723C
(zh)
*
|
1993-04-06 |
1999-11-24 |
艾博特公司 |
四环化合物、含有它们的药物组合物及其用途
|
KR100330942B1
(ko)
*
|
1994-03-02 |
2002-11-16 |
악조 노벨 엔.브이. |
설하또는협측투여용약학조성물
|
JP3274579B2
(ja)
*
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
NZ329953A
(en)
*
|
1996-04-12 |
1999-06-29 |
Janssen Pharmaceutica Nv |
Substituted tetracyclic n-oxide tetrahydrofuran derivatives, salts and stereoisomeric forms thereof for the treatment of cns cardiovascular or gastrointestinal disorders
|
AU7767598A
(en)
*
|
1997-05-26 |
1998-12-30 |
Akzo Nobel N.V. |
Salts of aromatic sulphonic acids
|
HRP20020305A8
(en)
*
|
2002-04-10 |
2009-03-31 |
GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. |
2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
|
HRP20020441A2
(en)
*
|
2002-05-21 |
2003-12-31 |
Pliva D D |
1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
|
HRP20030160A2
(en)
*
|
2003-03-06 |
2005-04-30 |
Pliva-Istra�iva�ki institut d.o.o. |
1-thiadibenzoazulene derivatives and biological action thereof
|
RU2005135454A
(ru)
*
|
2003-05-16 |
2006-06-27 |
Пфайзер Продактс Инк. (Us) |
Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами
|
HRP20030885A2
(en)
*
|
2003-11-03 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
|
HRP20030954A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva D.D. |
USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030959A2
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
|
HRP20030956A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
|
HRP20030958A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030955A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030957A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030953A2
(en)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20040104A2
(en)
*
|
2004-01-30 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
|
WO2005079807A1
(en)
*
|
2004-02-13 |
2005-09-01 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
|
EP1753460A2
(en)
*
|
2004-05-11 |
2007-02-21 |
Pfizer Products Inc. |
Combination of atypical antipsychotics and 5-ht1b receptor antagonists
|
CA2581188A1
(en)
*
|
2004-10-15 |
2006-04-20 |
Pfizer Inc. |
Treatment of bipolar disorders and associated symptoms
|
MX2007012446A
(es)
*
|
2005-04-07 |
2007-11-07 |
Organon Nv |
Compuestos intermediarios para la preparacion de trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz(2,3:6,7)- oxepino[4,5-c]pirrol.
|
EP1917267B1
(en)
*
|
2005-04-07 |
2008-12-24 |
N.V. Organon |
Crystal form of asenapine maleate
|
US7872147B2
(en)
|
2005-04-07 |
2011-01-18 |
N. V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
US7741358B2
(en)
*
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
WO2007046554A1
(ja)
*
|
2005-10-21 |
2007-04-26 |
Sumitomo Chemical Company, Limited |
ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
|
TW200817414A
(en)
*
|
2006-07-05 |
2008-04-16 |
Organon Nv |
Process for the preparation of asenapine and intermediate products used in said process
|
US7750167B2
(en)
*
|
2006-07-05 |
2010-07-06 |
N.V. Organon |
Process for the preparation of asenapine and intermediate products used in said process
|
PE20081457A1
(es)
*
|
2006-10-06 |
2008-10-18 |
Organon Nv |
Asenapina amorfa, procesos para prepararlas y su uso para tratar trastornos del sistema nervioso central
|
US7875729B2
(en)
*
|
2007-01-05 |
2011-01-25 |
Synthon Bv |
Process for making asenapine
|
WO2008148515A1
(en)
*
|
2007-06-05 |
2008-12-11 |
Synthon B.V. |
Intranasal administration of asenapine and pharmaceutical compositions therefor
|
JP5245428B2
(ja)
*
|
2007-07-06 |
2013-07-24 |
住友化学株式会社 |
トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
|
ATE527266T1
(de)
*
|
2008-01-04 |
2011-10-15 |
Organon Nv |
Herstellungsverfahren für asenapin und in diesem verfahren verwendete zwischenprodukte
|
CA2716080C
(en)
|
2008-02-20 |
2016-12-13 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
EP2321011A1
(en)
*
|
2008-06-25 |
2011-05-18 |
Pfizer Inc. |
Diaryl compounds and uses thereof
|
AU2010264670A1
(en)
|
2009-06-24 |
2012-01-19 |
Merck Sharp & Dohme B.V. |
Injectable formulations containing asenapine and method of treatment using same
|
TW201118102A
(en)
|
2009-07-29 |
2011-06-01 |
Organon Nv |
Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
|
US8779161B2
(en)
|
2010-06-18 |
2014-07-15 |
Dr. Reddy's Laboratories Limited |
Asenapine maleate
|
KR101810717B1
(ko)
|
2010-07-29 |
2017-12-19 |
라보라토리오스 레스비, 에스.엘. |
아세나핀을 제조하는 신규한 방법
|
WO2012068161A1
(en)
|
2010-11-15 |
2012-05-24 |
Agenebio, Inc. |
Pyridazine derivatives, compositions and methods for treating cognitive impairment
|
WO2012066565A2
(en)
|
2010-11-16 |
2012-05-24 |
Cadila Healthcare Limited |
Asenapine maleate amorphous and crystalline form and process for preparation thereof
|
EP2468750A1
(en)
|
2010-12-13 |
2012-06-27 |
Chemo Ibérica, S.A. |
Polymorphic forms of asenapine maleate and processes for their preparation
|
ES2575544T3
(es)
|
2010-12-24 |
2016-06-29 |
Medichem, S.A. |
Procedimientos para la preparación de 5-cloro-2-metil-2,3,3a,12b-tetrahidro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pirrol
|
WO2012123325A1
(en)
|
2011-03-11 |
2012-09-20 |
Medichem S.A. |
NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
|
ITMI20110734A1
(it)
|
2011-05-02 |
2012-11-03 |
Olon Spa |
Sali cristallini di asenapina
|
EP2524921A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Salts of Asenapine
|
EP2524919A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
|
WO2012156676A1
(en)
|
2011-05-18 |
2012-11-22 |
Laboratorios Lesvi S.L. |
Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
|
US9505771B2
(en)
|
2011-05-18 |
2016-11-29 |
Laboratories Lesvi S.L. |
Stable micronised monoclin form of asenapine maleate and its synthesis
|
WO2013024492A2
(en)
|
2011-07-01 |
2013-02-21 |
Megafine Pharma (P) Ltd. |
A process for the preparation of asenapine and novel salts thereof
|
US9145421B2
(en)
|
2011-07-20 |
2015-09-29 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine maleate
|
WO2013035109A1
(en)
|
2011-09-08 |
2013-03-14 |
Mylan Laboratories Ltd |
Improved process for the preparation of asenapine maleate
|
WO2013041604A1
(en)
|
2011-09-21 |
2013-03-28 |
Sandoz Ag |
Crystal form of asenapine maleate
|
EP2572703A1
(en)
|
2011-09-21 |
2013-03-27 |
Hexal AG |
Compressed oral dosage form for asenapine maleate
|
US20140336391A1
(en)
|
2011-11-28 |
2014-11-13 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine intermediate
|
CN103254201B
(zh)
*
|
2012-02-21 |
2016-04-13 |
四川科伦药物研究有限公司 |
一种阿塞那平的制备方法
|
WO2013190481A1
(en)
*
|
2012-06-21 |
2013-12-27 |
Alembic Pharmaceuticals Limited |
Process for preparing asenapine and salts of intermediates thereof
|
ITMI20121810A1
(it)
|
2012-10-24 |
2014-04-25 |
Chemo Iberica Sa |
Poliformi di maleato di asenapina e processo per la loro preparazione
|
CA2891122C
(en)
|
2012-11-14 |
2021-07-20 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
WO2014127786A1
(en)
|
2013-02-22 |
2014-08-28 |
Zentiva, K.S. |
Orally disintegrating pharmaceutical composition comprising asenapine
|
CN103113379A
(zh)
*
|
2013-03-12 |
2013-05-22 |
盛世泰科生物医药技术(苏州)有限公司 |
阿塞那平马来酸盐的合成工艺
|
CN103351393B
(zh)
*
|
2013-07-03 |
2016-04-06 |
华裕(无锡)制药有限公司 |
用于制备阿森那平之还原剂及阿森那平之制备方法
|
EP4032889A1
(en)
|
2013-12-20 |
2022-07-27 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
CN103772400A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
|
CN103772401A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
|
US11154510B2
(en)
|
2015-06-11 |
2021-10-26 |
Alrise Biosystems Gmbh |
Process for the preparation of drug loaded microparticles
|
EP3310785B1
(en)
|
2015-06-19 |
2024-11-20 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US11337932B2
(en)
|
2016-12-20 |
2022-05-24 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
|
CN115813888A
(zh)
|
2016-12-20 |
2023-03-21 |
罗曼治疗系统股份公司 |
包含阿塞那平的透皮治疗系统
|
JP2020525545A
(ja)
|
2017-06-26 |
2020-08-27 |
エルテーエス ローマン テラピー−ジステーメ アーゲー |
アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
|
MX2020013927A
(es)
|
2018-06-19 |
2021-03-02 |
Agenebio Inc |
Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
|
WO2019243432A1
(en)
|
2018-06-20 |
2019-12-26 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system containing asenapine
|
CN110958876B
(zh)
|
2018-06-20 |
2020-12-18 |
罗曼治疗系统股份公司 |
含有阿塞那平的透皮治疗系统
|
CN110183457A
(zh)
*
|
2019-06-27 |
2019-08-30 |
浙江天顺药业有限公司 |
一种阿塞那平及其制备方法
|
CN112830931A
(zh)
|
2019-08-13 |
2021-05-25 |
浙江奥翔药业股份有限公司 |
制备阿塞那平的方法
|
US11679407B2
(en)
*
|
2020-06-26 |
2023-06-20 |
Intel Corporation |
Liquid metal thermal interface material application
|
WO2023006954A1
(en)
|
2021-07-30 |
2023-02-02 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Asenapine for use in cancer
|
AU2023324882A1
(en)
|
2022-08-19 |
2025-03-20 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|